Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice

Abstract

Objective:

Fat Aussie mice (foz/foz) are morbidly obese, glucose intolerant and have liver steatosis that develops into steatohepatitis on a high-fat diet. The cannabinoid 1 receptor (CB1) antagonist SR141716 has been shown to improve obesity-associated metabolic complications in humans and rodent models. The aim of this study was to assess the effect of SR141716 in foz/foz mice.

Design:

Male wildtype (WT) and foz/foz mice were fed a chow or high-fat diet (45% saturated fat). Vehicle or SR141716 (10 mg kg−1 per day) was administered in jelly once daily for 4 weeks from 4 months of age.

Results:

Foz/foz mice were obese but had less epididymal adipose tissue mass than fat-fed WT mice despite being significantly heavier. Liver weight was increased by twofold in foz/foz compared with WT mice and showed significant steatogenesis associated with impaired liver function. Foz/foz and fat-fed WT mice were glucose intolerant as determined by oral glucose tolerance test. In chow-fed foz/foz mice, SR141716 reduced body weight, liver weight, reversed hepatosteatosis and glucose intolerance. Subcutaneous white adipose tissue gene expression of the macrophage-specific marker Cd68 reflected the improvements in the metabolic status by SR141716 in these mice.

Conclusion:

The results are consistent with the hypothesis that foz/foz mice have defective lipid metabolism, are unable to adequately store fat in adipose tissue but instead sequester fat ectopically in other metabolic tissues (liver) leading to insulin resistance and hepatic steatosis associated with inflammation. Our findings suggest that SR141716 can improve liver lipid metabolism in foz/foz mice in line with improved insulin sensitivity and adipose tissue inflammation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Despres JP, Lemieux I . Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881–887.

    Article  CAS  Google Scholar 

  2. Rutter MK, Meigs JB, Sullivan LM, D’Agostino Sr RB, Wilson PW . Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54: 3252–3257.

    Article  CAS  Google Scholar 

  3. Oakes ND, Bell KS, Furler SM, Camilleri S, Saha AK, Ruderman NB et al. Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. Diabetes 1997; 46: 2022–2028.

    Article  CAS  Google Scholar 

  4. Kahn SE, Hull RL, Utzschneider KM . Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840–846.

    Article  CAS  Google Scholar 

  5. Kunos G . Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 2007; 120 (9 Suppl 1): S18–S24; discussion S24.

    Article  CAS  Google Scholar 

  6. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171–3180.

    Article  CAS  Google Scholar 

  7. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053–3060.

    Article  Google Scholar 

  8. Pagotto U, Cervino C, Vicennati V, Marsicano G, Lutz B, Pasquali R . How many sites of action for endocannabinoids to control energy metabolism? Int J Obes 2006; 30: S39–S43.

    Article  CAS  Google Scholar 

  9. Engeli S, Jordan J . The endocannabinoid system: body weight and metabolic regulation. Clin Cornerstone 2006; 8 (Suppl 4): S24–S35.

    Article  Google Scholar 

  10. Despres JP, Golay A, Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–2134.

    Article  CAS  Google Scholar 

  11. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.[published erratum appears in Lancet. 2005;366(9483):370]. Lancet 2005; 365: 1389–1397.

    Article  CAS  Google Scholar 

  12. Nogueiras R, Rohner-Jeanrenaud F, Woods SC, Tschop MH . The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol 2008; 20 (Suppl 1): 147–151.

    Article  CAS  Google Scholar 

  13. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345–R353.

    Article  Google Scholar 

  14. Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006; 55: 3403–3410.

    Article  CAS  Google Scholar 

  15. Cota D, Sandoval DA, Olivieri M, Prodi E, D’Alessio DA, Woods SC et al. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17: 1641–1645.

    Article  CAS  Google Scholar 

  16. Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM et al. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006; 84: 353–359.

    Article  CAS  Google Scholar 

  17. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M . The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69: 471–478.

    Article  CAS  Google Scholar 

  18. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908–914.

    Article  CAS  Google Scholar 

  19. Arsov T, Silva DG, O’Bryan MK, Sainsbury A, Lee NJ, Kennedy C et al. Fat aussie--a new Alstrom syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol Endocrinol 2006; 20: 1610–1622.

    Article  CAS  Google Scholar 

  20. Hearn T, Spalluto C, Phillips VJ, Renforth GL, Copin N, Hanley NA et al. Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. Diabetes 2005; 54: 1581–1587.

    Article  CAS  Google Scholar 

  21. Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 2006; 342: 1152–1159.

    Article  CAS  Google Scholar 

  22. Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 2009; 24: 1658–1668.

    Article  CAS  Google Scholar 

  23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW . Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796–1808.

    Article  CAS  Google Scholar 

  24. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160–3169.

    Article  CAS  Google Scholar 

  25. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. (see comment). J Clin Invest 2005; 115: 1298–1305.

    Article  CAS  Google Scholar 

  26. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46: 122–129.

    Article  CAS  Google Scholar 

  27. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908–914.

    Article  CAS  Google Scholar 

  28. Migrenne S, Lacombe A, Lefevre AL, Pruniaux MP, Guillot E, Galzin AM et al. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2009; 296: R929–R935.

    Article  CAS  Google Scholar 

  29. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119: 28–36.

    Article  CAS  Google Scholar 

  30. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P . CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010; 59: 926–934.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded in part by the Sanofi-Aventis Australia Pty Limited (RIMON_L_02111).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K S Bell-Anderson.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bell-Anderson, K., Aouad, L., Williams, H. et al. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. Int J Obes 35, 1539–1548 (2011). https://doi.org/10.1038/ijo.2011.55

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2011.55

Keywords

This article is cited by

Search

Quick links